---
title: Azelaprag
slug: azelaprag
qid: 
snapshot: enwiki-001370557281
content_hash: 
license: CC BY-SA 4.0
source: https://en.wikipedia.org/w/index.php?oldid=1370557281
tags: [106462793, 106462794, 130859406, 20279306, 23118434, 23468805, 23603337, 27015373, 37750075, 48144539, 48508579, 50769796, 60213899, 63007578, 68150358, 72504547]
---

# Azelaprag

> [!note] Provenance
> Snapshot `enwiki-001370557281` · content root `…`
> Derived from <https://en.wikipedia.org/w/index.php?oldid=1370557281> · Licensed CC BY-SA 4.0

Azelaprag (original Amgen development code AMG 986, subsequently licensed to BioAge Labs and renamed BGE-105) is a drug which is a selective, small-molecule agonist for the apelin receptor. It was originally developed as a potential treatment for heart failure and has subsequently been investigated for other applications such as obesity and muscle wasting in elderly or bed-bound patients.

Azelaprag (original Amgen development code AMG 986, subsequently licensed to BioAge Labs and renamed BGE-105) is a drug which is a selective, small-molecule agonist for the apelin receptor. It was originally developed as a potential treatment for heart failure and has subsequently been investigated for other applications such as obesity and muscle wasting in elderly or bed-bound patients.
